Severe Hypernatraemia Secondary to Adipsia Associated With a Pituitary Macroadenoma in a Dog: A Case Report Authors: Gyo‐Bin Choo, Bum‐kyu Choi, Sooyoung Choi, Daji Noh, Ju‐Hyun An Published: 2026 ABSTRACT ABSTRACTBackgroundAdipsia is a rare disorder characterised by absence of thirst despite hyperosmolality, resulting from dysfunction of the hypothalamic thirst centre. In veterinary medicine, most reported cases of adipsia are associated with congenital forebrain abnormalities, whereas acquired causes in adult dogs are uncommon.Case presentationThis report describes a 9‐year‐old neutered male mixed‐breed dog presented with lethargy, anorexia, vomiting, recumbency, complete absence of voluntary water intake (adipsia) and intermittent tremors. Severe hypernatraemia (192 mmol/L) and hyperchloremia were identified on initial evaluation. Plasma aldosterone concentration was within the reference interval, excluding hyperaldosteronism. An ACTH stimulation test revealed hypercortisolemia, and abdominal ultrasonography demonstrated bilateral adrenal enlargement. Following controlled correction of hypernatraemia with intravenous fluid therapy, magnetic resonance imaging identified a pituitary macroadenoma occupying the sellar and suprasellar regions with mass effect toward the hypothalamus. Secondary adipsia due to hypothalamic compression was considered the most likely cause of hypernatraemia. Medical management with trilostane and cabergoline was initiated. Follow‐up imaging demonstrated mild tumour reduction, and serum sodium concentrations remained stable with assisted water supplementation during nine months of follow‐up.ConclusionThis case expands the recognised neurological manifestations of pituitary‐dependent hyperadrenocorticism and highlights pituitary macroadenoma as a potential cause of acquired adipsia and severe hypernatraemia in geriatric dogs.Clinical trial registrationNot applicable. Introduction Adipsia is a rare condition characterised by a complete absence of thirst despite hyperosmolarity caused by body water deficit or salt excess, resulting from dysfunction of the hypothalamic thirst centre (Goldkamp and Schaer 2007, McKenna et al. 1998). In dogs, reported clinical manifestations of adipsia most commonly include severe hypernatraemia, tremors, seizures, abnormal behaviours and circling, particularly in cases associated with congenital forebrain abnormalities such as corpus callosal defects (Gonçalves et al. 2014, Giannuzzi et al. 2025). In human medicine, disorders of thirst appreciation have been classified into types A through D based on osmoregulatory function and thirst perception (McKenna et al. 1998). In contrast, veterinary medicine lacks a widely accepted classification system for adipsia, and cases are typically described as primary or secondary depending on the presence of identifiable underlying structural abnormalities. In the veterinary literature, adipsia in dogs has predominantly been reported in pediatric patients, most often associated with congenital structural brain abnormalities, particularly involving the corpus callosum. Retrospective and case‐based studies have described electrolyte disturbances, including severe hypernatraemia, in dogs with corpus callosal defects and dysplasia (Gonçalves et al. 2014, Giannuzzi et al. 2025). However, primary adipsia without identifiable structural brain abnormalities has also been reported, albeit rarely (Caramalac et al. 2021). In cats, reports of adipsia remain limited to a small number of cases across a wide age range (Simpson et al. 2011, Miller et al. 2015, Evenhuis et al. 2021). Reports of adipsia associated with acquired intracranial disease in adult dogs and cats are scarce. Adipsia or hypodipsia resulting from hypothalamic involvement has been described in association with inflammatory and neoplastic intracranial lesions, including granulomatous meningoencephalitis and central nervous system lymphosarcoma (Simpson et al. 2011, Mackay and Curtis 1999). Nevertheless, adipsia associated with intracranial neoplasia in adult or geriatric dogs remains rare. To the authors’ knowledge, adipsia secondary to a pituitary macroadenoma has not been previously reported. This report describes a geriatric dog with severe hypernatraemia caused by adipsia associated with hypothalamic dysfunction due to a pituitary macroadenoma occupying the sellar region. Case Description A 9‐year‐old neutered male mixed‐breed dog weighing approximately 7.5 kg, mainly kept indoors, was referred from a local animal hospital to the Emergency and Critical Care Service at Kangwon National University Veterinary Teaching Hospital. The major presenting clinical signs included lethargy, anorexia, vomiting, recumbency, complete absence of voluntary water intake (adipsia) and intermittent tremors. The dog was up to date on routine vaccinations and deworming. Seven days before referral, the dog developed an acute fever and was presented to a local animal hospital, where symptomatic treatment, including fluid therapy and medications, was initiated. The fever resolved over the following days; however, lethargy, anorexia, vomiting and adipsia persisted. During this period, voluntary water intake progressively declined and ultimately ceased completely despite owner attempts to encourage drinking. Defecation frequency decreased, and the dog became increasingly weak, prompting referral for further evaluation. The dog had a history of polyuria and polydipsia several months earlier, followed by a gradual reduction in water consumption prior to the onset of complete adipsia. No history of significant outdoor exposure, toxin ingestion, trauma, or recent travel was reported. On presentation, physical examination revealed poor body condition (body condition score 2/9) and moderate dehydration (approximately 7%). The dog was recumbent but responsive. Rectal temperature was mildly elevated, while heart rate, respiratory rate and blood pressure were within acceptable limits. Cardiopulmonary auscultation was unremarkable. Neurologic examination did not reveal focal deficits; however, the owner reported intermittent tremors while the dog was recumbent. Initial laboratory evaluation revealed elevations in the liver enzyme panel, along with increased C‐reactive protein (CRP) and canine pancreatic lipase (cPL). Electrolyte analysis performed using venous blood gas analysis (VBGA) identified severe hypernatraemia, with a sodium concentration of 192 mmol/L (reference interval [RI]: 139–151 mmol/L), accompanied by hyperchloremia with a chloride concentration of 143 mmol/L (RI: 107–122 mmol/L), while potassium concentration remained within the reference range at 4.0 mmol/L (RI: 3.6–5.3 mmol/L) (Figure 1). Subsequent serum biochemistry analysis demonstrated electrolyte abnormalities consistent with the VBGA findings. Plasma aldosterone concentration was within the reference interval, thereby excluding hyperaldosteronism as a cause of hypernatraemia. An ACTH stimulation test demonstrated both pre‐ and post‐stimulation cortisol concentrations above the reference ranges (Figure 2). Although diabetes insipidus was considered as a differential diagnosis, plasma arginine vasopressin (AVP) concentration and urine osmolality were not measured. Serial serum electrolyte concentrations during hospitalisation. Changes in serum sodium (Na+), potassium (K+), and chloride (Cl−) concentrations over time during hospitalisation are shown. Severe hypernatremia was present at presentation, with gradual reduction in serum Na+ concentration over the treatment period. Serum Cl− concentration showed a similar decreasing trend, whereas serum K+ concentration remained relatively stable throughout hospitalisation. The shaded area represents the reference interval for serum chloride concentration. The dotted vertical line indicates the time of discharge. Serial ACTH stimulation test results and treatment regimen during follow‐up. Serum cortisol concentrations measured before (Pre) and after (Post) ACTH stimulation are shown over the follow‐up period. At initial evaluation (Day 0), the post‐ACTH cortisol concentration exceeded the upper measurable limit (>30 µg/dL). Following initiation of medical management, post‐ACTH cortisol concentrations gradually decreased and remained within or near the reference interval during follow‐up. Trilostane dosing (mg/kg) and cabergoline dosing (mg/kg/week) administered during the monitoring period are indicated below the graph. The shaded area represents the reference interval, and the arrow indicates the time of cabergoline initiation (Day 8). Abdominal ultrasonography revealed bilateral adrenal enlargement, with the right adrenal gland measuring 10.0 mm and 6.5 mm at the cranial and caudal poles, respectively, and the left adrenal gland measuring 6.8 mm and 6.6 mm. Diffusely decreased pancreatic echogenicity was also observed, consistent with concurrent pancreatitis. The dog was hospitalised for three days for correction of severe hypernatraemia. The calculated free water deficit was replaced using 5% dextrose in water. To minimise the risk of cerebral oedema associated with rapid correction, fluids were administered at a controlled rate with close neurologic monitoring. Serial electrolyte measurements were primarily obtained using VBGA during the correction period, and serum sodium concentration gradually decreased from 192 mmol/L to 163 mmol/L without the development of neurologic complications. Management of concurrent pancreatitis included antiemetic therapy, analgesics, gastrointestinal protectants, and prophylactic antimicrobial therapy, consisting of maropitant (1 mg/kg SC q24h; Cerenia inj., Zoetis, USA), tramadol (4 mg/kg IV q8h; Tridol inj., Yuhan, South Korea), esomeprazole sodium (1 mg/kg IV q12h; Nexium inj., AstraZeneka Korea CO., South Korea), amoxicillin–clavulanate (12.5 mg/kg IV q12h; Amocla inj., Kuhnil CO., South Korea), and metronidazole (10 mg/kg IV q12h; Metrynal inj., Daihan Pharm CO., South Korea). Clinical status, including mentation and appetite, progressively improved during hospitalisation. After discharge, the dog was transitioned to outpatient management. Given the combination of adipsia, severe hypernatraemia and endocrine abnormalities, an intracranial lesion affecting hypothalamic function was suspected. Two days after discharge, magnetic resonance imaging (MRI; 1.5‐Tesla unit, Vantage Elan; Canon Medical Systems, Tokyo, Japan) and computed tomography (Alexion; Toshiba, Otawara, Japan) of the brain were performed. Imaging revealed a pituitary macroadenoma involving the sellar region with mass effect toward adjacent hypothalamic structures. Tumour dimensions measured 17 × 21 × 17 mm on MRI and 16.2 × 19.2 × 18.6 mm on CT, as interpreted by the same imaging specialist (Figure 3). Magnetic resonance imaging (MRI) and computed tomography (CT) findings of a pituitary macroadenoma. T2‐weighted MRI images obtained on day 4 are shown in transverse (A) and sagittal (B) planes, revealing a pituitary mass (yellow arrows) measuring 17 × 21 × 17 mm. Contrast‐enhanced CT images acquired on day 4 are presented in transverse (C) and sagittal (D) planes, with the lesion measuring 16.2 × 19.2 × 18.6 mm. Follow‐up contrast‐enhanced CT images obtained on day 122 after treatment with trilostane and cabergoline are shown in transverse (E) and sagittal (F) planes, demonstrating a mild reduction in pituitary mass size to 14.5 × 18.7 × 15.3 mm. All measurements were performed by the same imaging specialist. Medical therapy was initiated with trilostane at a dosage of 0.5 mg/kg (PO q12h; Vetoryl, Dechra, UK) and cabergoline at a dosage of 0.07 mg/kg/week (PO q48h; Caberlactin, Dongkoo Bio & Pharma, South Korea). Three months after initiation of cabergoline therapy, follow‐up imaging was performed to assess tumour size. Because delayed anaesthetic recovery and haemodynamic instability had occurred during the previous MRI examination, follow‐up imaging was conducted using contrast‐enhanced CT under analgesia and sedation rather than general anaesthesia. Follow‐up CT demonstrated a mild reduction in pituitary mass dimensions to 14.5 × 18.7 × 15.3 mm, as assessed by the same imaging examiner (Figure 3). Over approximately six months of outpatient follow‐up, appetite, mentation, voluntary water intake, and vital parameters remained improved, and serum sodium concentrations were consistently maintained at approximately 150 mmol/L (Figure 4). Serial monitoring of serum electrolyte concentrations after discharge. Serum sodium (Na+), potassium (K+), and chloride (Cl−) concentrations measured during follow‐up after hospital discharge are shown. Sodium and chloride concentrations remained mildly elevated but relatively stable over the follow‐up period, whereas potassium concentration remained within a narrow range. The shaded area indicates the reference interval. Discussion Hypernatraemia in dogs is most commonly associated with free water deficit rather than sodium gain (Silverstein and Hopper 2014). Causes include pure water loss, hypotonic fluid loss and, less frequently, sodium retention, such as primary hyperaldosteronism (McClure and Dvir 2013). In the present case, the history of polyuria and polydipsia (PU/PD) for approximately three weeks followed by abrupt cessation of voluntary water intake strongly suggested progressive free water deficit secondary to impaired thirst perception. Primary hyperaldosteronism was excluded based on plasma aldosterone concentration, plasma renin activity and the absence of hypokalaemia or systemic hypertension (Galac et al. 2010, Harvey and Refsal 2013). Other causes of hypernatraemia, including third‐space loss, renal disease, or drug‐induced imbalance, were not supported clinically. Therefore, adipsia was considered the primary mechanism underlying the severe hypernatraemia. Adipsia is well characterised in human medicine, where it is classified physiologically according to thirst perception and arginine vasopressin (AVP) regulation (McKenna et al. 1998) and aetiologically as primary or secondary (Kothari et al. 2021, Pérez et al. 2019). In contrast, veterinary medicine lacks a clearly defined classification system, and most reported cases are described as primary regardless of structural findings (Jeffery et al. 2003, Miller et al. 2015). Reported veterinary cases have involved congenital forebrain malformations, inflammatory disease and lymphoma (Gonçalves et al. 2014, Simpson et al. 2011, Mackay and Curtis 1999). In this patient, MRI revealed a sellar and suprasellar mass consistent with a functional pituitary macroadenoma extending dorsally toward the hypothalamic region. The thirst osmoreceptors are located within the lamina terminalis of the anterior hypothalamus (McKenna et al. 1998), and dysfunction in this region can impair thirst perception. Although neurological signs associated with pituitary macroadenomas are typically attributed to optic chiasm or forebrain compression (Rapastella et al. 2023), involvement of the hypothalamic thirst centre is rarely emphasised. Given the presence of an acquired structural lesion affecting the hypothalamus, this case is most appropriately categorised as secondary adipsia. Differentiation from adipsic diabetes insipidus (DI) remains challenging. Plasma AVP concentration and urine osmolality were not measured in this case. However, normalisation of serum sodium concentration was achieved with assisted water intake alone, without desmopressin administration. This clinical response makes central DI less likely, although it cannot be definitively excluded. In this case, adipsia persisted for approximately one week before presentation, suggesting subacute hypernatraemia. Brain cells adapt to hyperosmolar states by accumulating intracellular osmolytes, reducing cellular dehydration (Verbalis 2010). This adaptive process may explain the relatively mild neurological signs observed despite severe hypernatraemia. Gradual correction of sodium concentration using isotonic crystalloid fluids combined with 5% dextrose in water resulted in safe normalisation without neurological deterioration (Braun et al. 2015) (Silverstein and Hopper 2014). Although optimal correction rates remain debated (Chauhan et al. 2019), careful monitoring allowed successful management in this case. Management of pituitary macroadenoma includes surgery, radiotherapy and medical therapy (De Fornel et al. 2007) (van Rijn et al. 2016, Rapastella et al. 2023). Because definitive treatment was declined, trilostane was initiated to control hypercortisolemia (Braddock et al. 2003). However, trilostane does not directly reduce tumour size and may theoretically increase ACTH stimulation (Teshima et al. 2009, Gil‐Cárdenas et al. 2007). Therefore, adjunctive tumour‐directed therapy was considered. Cabergoline, a dopamine D2 receptor agonist, has demonstrated anti‐proliferative effects in corticotroph tumours (Colao et al. 2000) (Castillo et al. 2008) and has been associated with pituitary tumour reduction in dogs with PDH (Castillo et al. 2008, Golinelli et al. 2023). Following combination therapy, tumour size reduction and partial recovery of spontaneous drinking behaviour were observed, supporting a structural contribution to the adipsia. Despite incomplete normalisation of thirst perception, long‐term stabilisation was achieved through owner‐assisted water supplementation. Serum sodium concentrations remained stable for over nine months. Favourable outcomes in adipsic hypernatraemia have been reported when adequate free water intake is maintained (Evenhuis et al. 2021, Gonçalves et al. 2014). Thus, restoration of sufficient daily water intake appears to be the primary determinant of prognosis. This report describes a single case without histopathologic confirmation of the pituitary mass. Plasma AVP concentration, urine osmolality and formal testing to definitively exclude central DI were not performed. Therefore, adipsic DI cannot be completely ruled out. Despite these limitations, the findings support hypothalamic dysfunction secondary to a pituitary macroadenoma as the most likely cause of adipsia in this dog. This case highlights the importance of recognising progressive reductions in water intake and considering intracranial disease in dogs presenting with persistent hypernatraemia and adipsia. Recent evidence suggests that ageing itself may reduce thirst sensitivity and voluntary water intake, increasing susceptibility to dehydration in geriatric dogs (Guelfi et al. 2025). Consequently, distinguishing age‐related changes in drinking behaviour from clinically significant disorders of thirst regulation may be challenging without regular monitoring and appropriate diagnostic evaluation. In selected cases, advanced imaging may be warranted to investigate potential intracranial causes of impaired thirst perception. Conclusion In geriatric dogs presenting with adipsia and secondary hypernatraemia, thorough history taking and early recognition are essential. Gradual correction of sodium imbalance and appropriate fluid therapy are critical for initial stabilisation. Intracranial imaging should be considered in dogs with adipsia to identify underlying causes, and pituitary macroadenoma should be included among differential diagnoses for acquired adipsia in adult dogs. Author Contributions Gyo‐Bin Choo: conceptualisation, investigation, resources, writing – original draft. Bum‐kyu Choi: resources, writing – review and editing. Daji Noh: writing – review and editing, resources. Sooyoung Choi: resources, writing – review and editing. Ju‐Hyun An: conceptualisation, investigation, resources, supervision, writing – review and editing. Funding The authors declare that financial support was received for the research, authorship and/or publication of this article. This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (RS‐2023‐00240708). Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.